Subscribe To

Price Alert Latest News Economic Calendar News

ASLN / Aslan Pharmaceuticals shares slide amid new data on atopic dermatitis treatment

Shares of Aslan Pharmaceuticals ASLN were down 32% premarket on Thursday after the company released new data from a clinical study of eblasakimab, an atopic dermatitis treatment. Among patients treated with the highest dose of the monoclonal antibody once every four weeks, 63% achieved at least a 75% reduction in an eczema area and severity index, the company said in a release, compared to 31% on placebo. Read More

Demo Live Account See Partner Details

Content Topics

Aslan

Pharmaceuticals

Slide

Amid

Data

Atopic

Dermatitis

Treatment

Stock

ASLN

Posted: Jul 6 2023, 08:22

Author Name: Market Watch

ASLN News

By Zacks Investment Research
July 7, 2023

ASLAN (ASLN) Down 25% on Mixed Results From Skin Disease Study

ASLAN (ASLN) reports mixed results from a mid-stage study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis. The stock price

By Market Watch
July 6, 2023

Aslan Pharmaceuticals shares slide amid new data on atopic dermatitis treatment

Shares of Aslan Pharmaceuticals ASLN were down 32% premarket on Thursday after the company released new data from a clinical study of eblasakimab, an

By GlobeNewsWire
July 5, 2023

ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis

SAN MATEO, Calif. and SINGAPORE, July 05, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-foc

By Zacks Investment Research
April 5, 2023

Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Atreca, Inc. (BCEL) have performed compared to their sector so far this year.

By Zacks Investment Research
March 9, 2023

Bears are Losing Control Over ASLAN Pharmaceuticals Ltd. (ASLN), Here's Why It's a 'Buy' Now

ASLAN Pharmaceuticals Ltd. (ASLN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately.

By Zacks Investment Research
March 2, 2023

Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Aspira (AWH) have performed compared to their sector so far this year.

By GlobeNewsWire
April 6, 2022

ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022

MENLO PARK, Calif. and SINGAPORE, April 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biophar

By Benzinga
January 21, 2022

ASLAN Pharma Kickstarts Mid-Stage Atopic Dermatitis Trial, Data Expected In 2023

ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has screened the first patient in its Phase 2b dose-ranging study of eblasakimab (ASLAN004) in adults with

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.